Bristol-Myers Squibb and AstraZeneca presented results from a 24-week Phase III study of Onglyza (the proposed trade name for saxagliptin). When used in combination with metformin, the drug produced significant reductions across all key measures of the glucose control studied.
The results were unveiled at the 44th European Association for the Study of Diabetes Annual Meeting. An NDA has already been submitted to the FDA and EMEA. If approved the drug could bring in $2 billion a year and will compete with Merck's DPP-4 inhibitor Januvia.
- check out the release